Chewy Stock, Morgan Stanley Says the 11% Sell-Off Went Too Far

At a Glance

Chewy stock faces an evidence gap: the retailer raised its fiscal year 2026 revenue and EBITDA guidance, yet the quality of its Q2 growth and earnings left investors unconvinced. On Sept. 9, 2026, Morgan Stanley reviewed Chewy’s results, reduced its price target from $37 to $36, maintained an Overweight rating and argued that the earnings-day decline of 11% was excessive, according to Yahoo Finance.

The tension is between reported expansion and the performance of the underlying business. Chewy generated $3.33 billion of net sales in Q2 fiscal 2026, up 7.3% year over year, but organic growth excluding SmartPak and Modern Animal was 5.7% and decelerated by about 120 basis points from Q1.

Why Chewy’s Q2 Growth Quality Matters Now

Chewy operates a subscription-driven retail business selling pet food, medicine and supplies. Organic growth—the portion excluding contributions from the SmartPak and Modern Animal acquisitions—is the cleaner measure of whether that established operation is accelerating on its own.

The 7.3% year-over-year increase in Q2 fiscal 2026 net sales therefore tells only part of the story. The 5.7% organic rate shows that acquired revenue lifted the reported result, while the 120-basis-point slowdown from Q1 indicates that the underlying growth trajectory weakened during the quarter.

Morgan Stanley views approximately 6% year-over-year organic growth as a reasonable baseline under current macro conditions. That creates a narrow but important distinction: stabilization near 6% could support the existing business case, but a higher valuation would require positive revisions to organic estimates rather than another quarter that merely holds the line.

The stock’s reaction reflects that distinction. Chewy fell 11% on the Sept. 9 earnings day and, according to Yahoo Finance, was down 36.22% year to date, 39.96% over the preceding year and 71.89% over a five-year holding period. Those declines do not establish what happens next, but they show how little tolerance investors have left for growth that depends on acquisitions or earnings support that will not recur.

The Earnings Beat Was Less Durable Than the Headline

Chewy raised its fiscal year 2026 revenue and EBITDA guidance, normally a constructive signal. Exact guidance figures were not provided in the available facts, however, and the composition of the EBITDA result limits what investors can infer from the increase.

Approximately $15 million of the Q2 fiscal 2026 EBITDA beat came from one-time items. Excluding those items, the midpoint of fiscal year 2026 EBITDA guidance decreased by about 6 basis points. The headline guidance raise and the adjusted movement therefore point in different directions: one improves the reported outlook, while the other suggests less underlying margin support.

Stock-based compensation also increased 17% quarter over quarter in Q2 fiscal 2026. That does not by itself determine operating performance, but it adds another checkpoint when investors assess whether EBITDA growth is translating into higher-quality earnings.

Morgan Stanley summarized the valuation tension directly: “Given underlying fundamentals were in-line, we think the -11% move is overdone.” The firm also warned, “But it's hard to argue for a meaningful re-rating until we see positive organic estimate revisions.” Its Overweight rating is therefore a conditional thesis, not confirmation that a recovery has begun.

Key Debates

• Reported growth versus organic demand: Chewy’s Q2 fiscal 2026 net sales rose 7.3% year over year, while organic growth excluding SmartPak and Modern Animal was 5.7%. The investment case strengthens only if the underlying rate stops decelerating and estimates begin moving higher.
• Guidance versus earnings quality: Fiscal year 2026 revenue and EBITDA guidance increased, but roughly $15 million of the quarterly EBITDA beat came from one-time items. Excluding them, the EBITDA guidance midpoint declined by approximately 6 basis points.
• Expansion versus execution: Modern Animal and SmartPak broaden Chewy’s operations, while its healthcare business was described as growing. The unresolved issue is whether those assets and the redesigned Chewy+ program can produce sustainable organic acceleration.
• Valuation upside versus scenario risk: Morgan Stanley’s $36 discounted-cash-flow price target sits between a $55 bull case and a $14 bear case. Those outcomes depend on growth and margin assumptions that Chewy has not yet achieved.

Modern Animal, SmartPak and Chewy+ Shape the Next Phase

Chewy acquired veterinary platform Modern Animal in April 2026 and SmartPak, also identified as SmartEquine, in late 2025. Morgan Stanley modeled fiscal year 2026 revenue contributions of $100 million from Modern Animal and $80 million from SmartPak.

Those contributions help explain the gap between total and organic growth. They also make future disclosures important: investors need to separate acquired revenue from improvement inside the established subscription-driven business. Chewy’s healthcare operation was described as growing, but the facts supplied do not quantify its growth or margins.

The redesigned Chewy+ membership program is the other potential variable. Management said it would launch “very shortly,” while Morgan Stanley identified possible early adoption in the second half of 2026 as a catalyst that could support a more aggressive fiscal 2027 rollout.

The exact launch date and adoption level remain unknown. Chewy+ can affect the thesis only after measurable customer response emerges; until then, it is a prospective program rather than demonstrated growth.

Related Stocks & Sectors

• Chewy (CHWY): The company is directly exposed to the debate over pet-retail demand, subscription-driven purchases, organic growth, healthcare expansion and Chewy+ adoption. Q2 fiscal 2026 results and Morgan Stanley’s revised $36 price target are specific to this stock.
• Pet retail and services: Chewy’s mix spans food, medicine, supplies and a growing healthcare business. The supplied evidence does not establish effects on any other listed company, so no peer-stock read-through is warranted.

Morgan Stanley’s Fiscal 2027 Valuation Test

Morgan Stanley estimates that Chewy could target fiscal 2027 incremental margins of approximately 15% to 18%. At the firm’s estimated 6.4% fiscal 2027 revenue growth, that would translate into about 50 to 70 basis points of EBITDA margin expansion, below the prior trend of roughly 100 basis points of margin additions.

This sets up a two-variable test. Faster revenue growth could compensate for a lower rate of margin expansion, while stronger margins could support the case if growth remains close to the estimate. Weakness in both would leave little support for a meaningful re-rating.

The firm’s $36 discounted-cash-flow price target assumes 7% revenue growth through fiscal 2030, a long-term EBITDA margin near 10% and an 8.5 times fiscal 2027 EBITDA valuation multiple. At the approximately $21 share price discussed, Chewy also traded near 8.5 times estimated fiscal 2027 EBITDA, while Morgan Stanley projected a 16% compound annual EBITDA growth rate through 2029.

The wider scenario range shows the sensitivity of that valuation. Morgan Stanley’s $55 bull case requires 8% revenue growth, successful scaling of Chewy+ and clinics, and a 13% EBITDA margin. Its $14 bear case assumes only 4% revenue growth and continued competitive pressure; which scenario materializes is unknown.

What to Watch

• Organic growth at the next earnings report: Compare the next rate with Q2 fiscal 2026’s 5.7% and Morgan Stanley’s approximately 6% baseline. Positive estimate revisions, not merely stability, are the firm’s stated condition for a meaningful re-rating.
• Chewy+ adoption: Look for a confirmed launch and measurable early adoption in the second half of 2026. Management has not supplied an exact launch date or adoption figure.
• Recurring EBITDA: Separate operating progress from one-time items after approximately $15 million supported the Q2 fiscal 2026 EBITDA beat. Track whether the guidance midpoint improves without similar support.
• Fiscal 2027 growth and margins: Test reported results against Morgan Stanley’s 6.4% revenue-growth estimate, 15% to 18% incremental-margin range and 50 to 70 basis points of projected EBITDA margin expansion.

Overall Outlook

The bullish argument is that the 11% earnings-day sell-off discounted more weakness than the in-line underlying fundamentals justified. Chewy still raised fiscal year 2026 revenue and EBITDA guidance, Morgan Stanley retained its Overweight rating, and Modern Animal, SmartPak, the healthcare business and Chewy+ provide several paths to a broader revenue base.

The bearish argument is rooted in current evidence. Organic growth slowed to 5.7%, one-time items supplied approximately $15 million of the EBITDA beat, the adjusted guidance midpoint slipped by about 6 basis points, and stock-based compensation rose 17% quarter over quarter.

Chewy’s next inflection will not be established by the $36 target alone. It will emerge from organic estimate revisions, recurring EBITDA performance, confirmed Chewy+ adoption and the balance between revenue growth and margin expansion in fiscal 2027.

FAQ

What is Morgan Stanley’s price target for Chewy stock?

Morgan Stanley lowered its Chewy price target from $37 to $36 after reviewing Q2 fiscal 2026 results. The firm maintained an Overweight rating, while TheStreet reported that the average 12-month target from 17 analysts over the prior three months was $29.

What do Morgan Stanley’s bull and bear cases imply for Chewy?

The $55 bull case assumes 8% revenue growth, successful scaling of Chewy+ and clinics, and a 13% EBITDA margin. The $14 bear case assumes 4% revenue growth and continued competitive pressure, and neither scenario is assured.

When will the redesigned Chewy+ program launch?

Chewy management described the launch timing only as “very shortly.” Morgan Stanley identified the second half of 2026 as the window in which early adoption could become a catalyst, but the exact launch date and adoption level are unknown.

This article was independently written by OneDayTrading from public reporting. Read the original (Yahoo Finance)